Amgen Phase lll PAVES Study evaluating Neulasta met primary endpoint Amgen announced results from Pegfilgrastim and Anti-VEGF Evaluation Study, PAVES, a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer. FOLFOX and FOLFIRI are two of the most commonly used chemotherapy regimens for colorectal cancer. The study met its primary endpoint, with Neulasta significantly reducing the incidence of febrile neutropenia. Febrile neutropenia is a low white blood cell count accompanied by a fever.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Subscribe for More Information